Oligonucleotide nSR100 Inhibitor for Small Cell Lung Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for small cell lung cancer (SCLC) are limited by high side effects, tolerance issues, and the lack of effective therapeutic agents, particularly after recurrence, where existing antitumor agents are less effective and often contraindicated for patients with interstitial pneumonia.
Innovation Solution
Development of an oligonucleotide with nSR100 gene expression inhibiting activity, specifically designed to bind to the human nSR100 gene, which can be used as a therapeutic agent for SCLC, potentially reducing tumor growth and improving treatment outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy (PE therapy or PI therapy) is used for SCLC treatment, then initial tumor control can be achieved, but the incidence rate of side effects such as diarrhea is significantly high and tolerance to chemotherapy is developed upon recurrence
Solution Approach 1:
The patent changes the therapeutic parameter from conventional chemotherapy agents (cisplatin, etoposide, irinotecan) to a novel oligonucleotide agent (LNA-ASO) that specifically targets nSR100 gene expression. This parameter change enables effective tumor control through gene silencing while avoiding the severe side effects and tolerance issues associated with traditional chemotherapy, particularly diarrhea and interstitial pneumonia complications
Solution Approach 2:
The patent extracts and targets the specific molecular mechanism driving SCLC progression by silencing the nSR100 gene, which is abnormally expressed in SCLC cells. This extraction of the pathological mechanism allows for precise therapeutic intervention that eliminates tumor control efficacy while avoiding the harmful side effects of conventional chemotherapy
2Reliability
If irinotecan is used in PI therapy, then tumor control can be achieved, but it is contraindicated for patients with interstitial pneumonia
Solution Approach 1:
The patent changes the therapeutic agent from irinotecan (a chemotherapy drug with contraindications) to an oligonucleotide-based nSR100 silencing agent. This parameter change removes the contraindication for patients with interstitial pneumonia while maintaining effective tumor control through specific gene silencing activity
Solution Approach 2:
The patent introduces an intermediary mechanism (nSR100 gene silencing via LNA-ASO) that mediates tumor control without involving the toxic pathways activated by irinotecan. This intermediary approach achieves therapeutic efficacy while bypassing the harmful effects that cause contraindications in patients with interstitial pneumonia
3Adaptability or versatility
If nSR100 gene expression is inhibited using the oligonucleotide, then a novel therapeutic approach for SCLC is provided, but this is a newly developed agent requiring validation
Solution Approach 1:
The patent performs preliminary validation by demonstrating that the oligonucleotide specifically binds to the nSR100 gene and inhibits its expression in vitro and in vivo. These preliminary actions provide foundational evidence for the novel therapeutic approach's reliability before broader clinical application
Solution Approach 2:
The patent establishes feedback mechanisms to evaluate the oligonucleotide's effectiveness by measuring nSR100 gene expression levels and tumor response. This feedback system allows for validation and optimization of the novel therapeutic approach, ensuring its reliability through systematic assessment
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The oligonucleotide effectively inhibits nSR100 gene expression, providing a novel therapeutic approach for SCLC that may reduce side effects and improve treatment efficacy, including in cases where traditional chemotherapy is contraindicated.
Implementation Method 1
the oligonucleotide comprises at least one nucleoside structure represented by Formula (I)... the oligonucleotide can bind to a human nSR100 gene
Data Source
AI summary
Disclosed is an oligonucleotide or a pharmacologically acceptable salt thereof, wherein the oligonucleotide comprises at least one defined nucleoside structure, can bind to a human nSR100 gene and has human nSR100 expression inhibiting activity. The oligonucleotide has a length of 12 to 20 mer, and is complementary to a defined target region. Further, disclosed is an nSR100 gene expression inhibitor and a cancer therapeutic agent containing the oligonucleotide or the pharmacologically acceptable salt thereof. The cancer therapeutic agent is used for treatment of small cell lung cancer, prostate cancer, or breast cancer.